Skip Ribbon Commands
Skip to main content
Sign In
{{'GLOBAL_MESSAGE_OR' | translate}}
{{'ELOQUA_BANNER_ACCEPT' | translate}}
{{'ELOQUA_BANNER_DECLINE' | translate}}
Plasma Exchange
A Clear Road to Results for MG and GBS Patients
Overview MG GBS How It Works Safety Resources References


American Society for Apheresis. Guidelines for therapeutic apheresis clinical privileges. J Clin Apher. 2007;22(3):181-182.

Chevret S, et al. Plasma exchange for Guillain-Barré syndrome (review). Cochrane Database of Systematic Reviews. 2017(2).

Cortese I, Chaudhry V, Yuen T, et al. Evidence-based guideline update: Plasmapheresis in neurologic disorders. Neurology. 2011;76(3):294-300.

Derksen RS. The efficacy of plasma exchange in the removal of plasma components. J Lab Clin Med. 1984;104:346-354.

Ebadi H, Barth D, Bril V. Safety of plasma exchange therapy in patients with myasthenia gravis. Muscle & Nerve. 2013;47(4):510-514.

Hund EF, Borel CO, Cornblath DR, Hanley DF, McKhann GM. Intensive management and treatment of severe Guillain-Barre syndrome. Crit Care Med. 1993;21(3):443-446.

Elovaara I, Apostolski S, van Doorn P, et al. EFNS guidelines for the use of intravenous immunoglobulin in treatment of neurological diseases. Eur J Neurol. 2008;15(893-908).

Guptill J, Sanders D, Evoli A. Anti-MuSK antibody myasthenia gravis: clinical findings and response to treatment in two large cohorts. Muscle Nerve. 2011;44(1):36-40.

Guptill JT, Juel VC, Massey JM, et al. Effect of therapeutic plasma exchange on immunoglobulins in myasthenia gravis. Autoimmunity. 2016;49(7):472-479.

Hund E, Borel C, Cornblath D, Naley DM. Intensive management and treatment of severe Guillain-Barre syndrome. Crit Care Med. 1993;21(3):443-446.

Kaynar L, Altuptas F, Aydogedu T, et al. Therapeutic plasma exchange in patients with neurologic diseases: retrospective multicenter study. Transfus Apher Sci. 2008;38(2):109-115.

Mortzell Henriksson M, Newman E, Witt V, et al. Adverse events in apheresis: An update of the WAA registry data. Transfus Apher Sci. 2016;54(1):2-15.

Pasnoor M, Wolfe G, Nations S, et al. Clinical findings in MuSK-antibody positive myasthenia gravis: A U.S. experience. Muscle Nerve. 2010;41(3):370-374.

Quereshi A, Choudhry M, Akbar M, et al. Plasma exchange versus intravenous immunoglobulin treatment in myasthenic crisis. Neurology 1999;52(3):629-632.

Raphaël JC, Chevret S, Hughes RA, Annane D. Plasma exchange for Guillain-Barré syndrome. Cochrane Database Syst Rev. 2012(7).

Reeves H, Winters J. The mechanisms of action of plasma exchange. Br J Haematol. 2014;164(3).

Sanders DB, Wolfe GI, Benatar M, et al. International consensus guidance for management of myasthenia gravis: Executive summary. Neurology. 2016;87(4):419-425.

Saperstein D, Barohn R. Management of myasthenia gravis. Semin Neurology. 2004;24(1):41-48.

Schwartz J, Padmanabhan A, Aqui N, et al. Guidelines on the use of therapeutic apheresis in clinical practice—Evidence-based approach from the writing committee of the American Society for Apheresis: The seventh special issue. J Clin Apher. 2016;31(3):149-162.

Sorgun M, Erdogan S, Bay M, et al. Therapeutic plasma exchange in treatment of neuroimmunologic disorders: Review of 92 cases. Transfus. Apher Sci. 2013;49(2):174-180.

Szczeklik W, Wawrycka K, Wludarcyzk A, et al. Complications in patients treated with plasmapheresis in the intensive care unit. Anesthesial Intensive Ther. 2013;45(1):7-13.

Tormey C. Improved plasma removal efficiency for therapeutic plasma exchange using a new apheresis platform. Transfusion. 2010;50(2):471-477.

Trikha I, Singh S, Goyal V, Shukla G, Bhasin R, Behari M. Therapeutic plasma exchange in the treatment of neuroimmunologic disorders: review of 50 cases. Neurol. 2007;254:989-995.

Vincent A. Autoantibodies in neuromuscular transmission disorders. Ann Indian Acad Neurol. 2008;11(3):140-145.

Vincent A. An update on antibody-mediated diseases. Advances in Clinical Neuroscience & Rehabilitation. 2010;10(1):8-11.

Winters J. Plasma exchange: concepts, mechanisms, and an overview of the American Society for Apheresis Guidelines. Hematology. 2012:7-12.

Safety Information


  • No known contraindications for the system's use, except for those associated with all automated apheresis systems
  • The infusion of certain solutions and replacement fluids may be contraindicated in some patients

Possible patient reactions

  • Anxiety, headache, light-headedness, digital and/or facial paresthesia, fever, chills, hematoma, hyperventilation, nausea and vomiting, syncope (fainting), urticaria, hypotension and allergic reactions

Reactions to transfused blood products can include1

  • Fever, circulatory overload, shock, allergic reactions, alloimmunization, graft-versus-host disease and transmission of infection

Restricted to prescription use only

  • Operators must be familiar with the system's operating instructions
  • Procedures must be performed by qualified medical personnel
  • A supervisory practitioner may supervise from a physician office or other nonhospital space that is not officially part of the hospital campus as long as he or she remains immediately available2

1AABB (ed.), et al. Circular of Information for the Use of Human Blood and Blood Components. Tenth edition. 2006. Council of Europe Publishing, Seattle, WA.

2American Society for Apheresis. Guidelines for therapeutic apheresis clinical privileges. J Clin Apher. 2007;22(3):181-182.

Medical information request
Find an apheresis center near you

International Content. Approved labeling, indications and instructions may vary by country. Reference the Instructions for Use labeling for a complete listing of indications, warnings and precautions.


{{'SEARCH_MODAL_TITLE' | translate }}
{{'SEARCH_MODAL_OR' | translate }}

{{'SEARCH_MODAL_BROWSE' | translate }}
{{$index+1}}. {{s.label}}